The much anticipated and hoped for excitement surrounding the announcement of Phase 2, has turned out to be another 'one day wonder' and like The Lancet, just another prelude to another unending period of 'nothing' pr's' with declining share prices, while the shorts and mm have fun making money in their 'playgound'.
So much for the start of Phase 2.
Just another desperate scenario, signifying next to nothing for shareholders except a declining share price easily heading to $3. and perhaps much lower with year end selling on the horizon, while the company keeps struggling to stay alive.
My goodness, Ocata has all of ONE INDIVIDUAL ENROLLED, whatever that means?
Can't imagine much excitement at the old phase 1 clinical sites to commit their staff and their capital.
My hoped for excitement has turned to zilch as a viable investment going forward.
The hard reality is this is just a company going nowhere for investor but down and down in share price, with momentary blips to keep the 'game' going.
Sad, but a movie seen tons of time over the years with other unsuccessful biotechs.
